Stay updated with breaking news from அஜி உயிர் பார்மா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Antibody-Drug Conjugate Therapeutic Window Enhancement, Upcoming Webinar Hosted by Xtalks prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
SAN DIEGO, May 25, 2021 /PRNewswire/ Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, today announced ....
Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(1) SAN DIEGO and BURLINGAME, California, Jan. 27, 2021 /PRNewswire/ Ajinomoto Bio-Pharma Services ( Aji Bio-Pharma ), a leading provider of biopharmaceutical contract development and manufacturing services, and Humanigen, Inc. (NASDAQ: HGEN) ( Humanigen ), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab, today announced the companies will be expanding their manufacturing agreement for the fill finish supply of lenzilumab, which is one of the few Phase 3 treatment options in development for patients hospitalized with COVID-19. Aji Bio-Pharma will assume a key role in simplifying the supply chain efforts for Humanigen by providing drug product aseptic fill finish services at its San Diego facility to support continued clinical trial efforts through potential commercialization. Humanigen is actively enrolling patients in a Phase 3 study in the U.S. and Brazi ....
Recro Announces Executive Changes David Enloe Named President and Chief Executive Officer December 16, 2020 07:00 ET | Source: Recro Pharma, Inc. Recro Pharma, Inc. Malvern, Pennsylvania, UNITED STATES MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today. Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CD ....